GIST Support International - logo

Current Trials for GIST Cancer
GIST Imagery

Current Trials for GIST Cancer

Current clinical trials for GIST (gastrointestinal stromal tumor) are linkable entries in the table below, grouped by the type of drug being evaluated, plus drug combinations.

Maps of Trial Locations

When you click this link you will see a world map of GIST trials at the clinicaltrials.gov website.  In countries where there are trials you will see a small white block with a black number indicating how many trials are open there.  Click the black number to zoom in on the geographic area of your choice.  For example, if you click on the USA or Europe, another map will open showing trials in each state or country.  Click again on the state or country of your choice to see which trials are available there.  NOTE that some trials listed in the table below will NOT appear on this map if GIST is not specifically listed in the trial protocol; for example, trials for any solid tumor may not appear.  Therefore, the listing in the following table provides a larger selection of trials for GIST.

GIST Trials Grouped by Type of Drug

Click a bulleted link below to jump to that section of trial listings.

  • Tyrosine Kinase Inhibitors of KIT, PDGFR etc 
  • HSP90 Inhibitors 
  • Inhibitors of Targets Downstream of KIT & PDGFR
  • Cell Cycle Inhibitors
  • Inhibitors of Insulin-Related Growth Factor Pathway
  • Drug Combination Trials
  • Angiogenesis Inhibitors
  • Other Trials
  • Observational and Diagnostic Trials

    Tyrosine Kinase Inhibitors of KIT, PDGFR etc

    Trial Name (click for link)PhaseID & Status
    Nilotinib (Tasigna)
    Nilotinib in Advanced GISTIINCT00760782
    recruiting
    Open-Label Study of Nilotinib Versus Imatinib in GIST PatientsIIINCT00785785
    recruiting
    Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibIINCT00756509
    recruiting
    Randomized Phase III Trial Comparing Nilotinib 800 mg_To Imatinib 800 mg for the Treatment of Patients with Advanced and/or Metastatic GIST Refractory to Imatinib 400 mgIIINCT00751036
    not yet recruiting
    Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinase (TK) InhibitorIINCT00633295
    not yet recruiting
    Pazopanib
    A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior TherapyIIINCT00753688
    recruiting
    Imatinib
    Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)IINCT00867113
    not yet recruiting
    Imatinib Mesylate in Treating Patients With Liver Metastasis From Gastrointestinal Stromal TumorIINCT00764595
    recruiting
    Study comparing 12 months versus 36 months of Imatinib in the treatment of Gastrointestinal stromal Tumor (GIST)IIINCT00116935
    recruiting
    Prospective Multicentric Randomized Study of Glivec in Advanced Gastointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs. MaintenanceIIINCT00367861
    recruiting
    Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorIINCT00112632
    recruiting
    Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal TumorIINCT00290485
    recruiting
    Imatinib Mesylate or Observation Only in Treating Patients Who have Undergone Surgery for Localized Gastointestinal Stromal TumorIII
    NCT00103168
    recruiting
    Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorspilotNCT00580281
    recruiting
    Sunitinib
    Safety and Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsIIIb
    NCT00372567
    recruiting
    A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment on a Previous Sunitinib StudyIIINCT00428220
    recruiting
    Post Marketing Surveillance Study To Observe Safety and Efficacy Of Sutent


    IV

    NCT00444795
    admitting by invitation only
    A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SUO11248IIINCT00094029
    recruiting
    Rollover Protocol for Other Sutent ProtocolsIINCT00798889
    recruiting
    Safety and efficacy of Sunitinib Malate in Chinese PatientsIVNCT00793871
    recruiting
    Sorafenib
    Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate or Sunitinib MalateIINCT00265798
    recruiting
    Dasatinib
    Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsIINCT00568750
    recruiting
    Trial of Dasatinib in Advanced SarcomasIINCT00464620
    recruiting
    Masitinib (AB1010)
    Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal TumourIIINCT00812240
    recruiting
    MP470
    Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
    INCT00894894
    recruiting
    MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or LymphomaINCT00504205
    recruiting

    HSP90 Inhibitors

    Trial Name (click for link)PhaseID & Status
    Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid TumorsINCT00618735
    recruiting
    SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment, recruiting, I

    NCT00644072
    recruiting

    Safety Study of Pharmokinetics of XL888 in Adults With Solid TumorsINCT00796484
    17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasINCT00096005
    recruiting
    Study of STA-9090, Administered Once-Weekly in Patients With Solid TumorsINCT00687934
    recruiting
    Study of STA-9090, Administered Twice-Weekly in Patients With Solid TumorsINCT00688116
    recruiting
    A Phase 1 Dose Escalation Study of IPI-493INCT00724425
    recruiting
    Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor MalignanciesINCT00506805
    recruiting
    Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsI-IINCT00526045
    recruiting
    An Open-Label 18FDG-PET Pharmocodynamic Assessment of the Effect of BIIB021 In Subjects With Gastrointestinal Stromal Tumors (GIST)IINCT00618319
    recruiting

    Inhibitors of Targets Downstream of KIT & PDGFR

    Trial Name (click for link)PhaseID & Status
    PI3K/AKT inhibitor
    Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerI/IINCT00620594
    recruiting
    PI3K inhibitor
    A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableINCT00876122
    recruiting
    A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable, INCT00876109
    recruiting
    Others
    Treatment of Patients with RAD001 Who Have Had Progressive Sarcoma
    II
    NCT00767819
    Recruiting
    Study of XL281 in Adults With Solid TumorsI

    NCT00451880
    Recruiting

    Treatment of Patients with RAD001 Who Have Had Progressive SarcomaII

    NCT00767819
    Recruiting

    Study of Single Agent Perifosine for recurrent Pediatric Solid Tumors
    INCT00776867
    Recruiting
    Study of Oral OSI-027 in Patients With Advanced Solid Tumours/LymphomaINCT00698243
    recruiting
    Phase I Trial of Oral PX-866INCT00726583
    recruiting
    Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) StudyIIINCT00538239
    recruiting
    Study of BEZ235 for Advanced Solid MalignanciesINVCI0635
    recruiting

    A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PIKinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors

    Inot listed
    recruiting
    Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid TumorsINCT00486135
    recruiting
    Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid TumorsINCT00485719
    recruiting

    A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

    I/IINCT00600275
    recruiting

    Cell Cycle Inhibitors

    Trial Name (click for link)PhaseID & Status
    Gemcitabine and Flavopiridol in Treating Patients With Solid TumorsINCT00072436
    recruiting
    Flavopiridol in Treating Patients With Locally Advanced or Metastatic Solid TumorsINCT00112684
    recruiting
    Solid Tumors Using Ixabepilone and DasatinibINCT00717704
    recruiting

    Inhibitors of Insulin-Related Growth Factor Path

    Trial Name (click for link)PhaseID & Status
    Cixutumumab (AMC-A12) in Treating Patients With Relapsed or Refractory Solid TumorsIINCT00831844
    recruiting
    A Study of R1507 in Patients With Recurrent or Refractory SarcomaIINCT00642941
    recruiting
    A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid TumorsINCT00560144
    recruiting
    Phase 1 Study of Continuous OSI-906 DosingINCT00514007
    recruiting
    Phase 1 Study of Intermittent OSI-906 DosingINCT00514306
    recruiting
    Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid TumorsINCT00729833
    recruiting
    A Combination Study With MK8669 (Deforolimus) and MK0646 in Patients With Advanced CancerINCT00730379
    recruiting
    Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid TumorsINCT00555724
    recruiting

    Drug Combination Trials

    Trial Name (click for link)PhaseID & Status
    Sorafenib (Nexavar) combinations
    RDEA119 and Sorafenib Combination Dose Escalation StudyI-IINCT00785226
    recruiting

    Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

    INCT00303797
    recruiting
    Phase 1 Study With Sorafenib and Sirolimus INCT00509613
    recruiting
    Phase I Vorinostat + Sorafenib in Patients With Advanced Solid TumorsINCT00635791
    recruiting
    Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue SarcomaI-IINCT00541840
    recruiting
    Sorafenib/Docetaxel Dose Escalation TrialINCT00562523
    recruiting
    HSP90 Inhibitor Combinations
    Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid TumorsINCT00878423
    recruiting
    Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid TumorsINCT00606814
    recruiting
    17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasINCT00096005
    Recruiting
    Imatinib (Gleevec) or Sunitinib (Sutent) combinations
    A Phase I Trial of Bortezomib and SunitinibINCT00720148
    recruiting
    Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid TumorsINCT00729833
    recruiting
    Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsINCT00573404
    Recruiting
    Phase I Study of Imatinib Mesylate and SUO11248 (Sunitinib) for Patients with GISTINCT00495001
    recruiting
    Imatinib Mesylate With or Without Bevacizumab in Treating Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorIIINCT00324987
    recruiting
    Bevacizumab and Sunitinib in Treating Patients With Solid TumorsINCT00357318
    recruiting
     Other combinations
    I-IINCT00819169
    recruiting
    Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced CancersINCT00781846
    Recruiting
    Solid Tumors Using Ixabepilone and DasatinibINCT00717704
    recruiting

    Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

    INCT00227513
    recruiting
    Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid TumorsINCT00729833
    recruiting
    IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced CancersINCT00678769
    recruiting
    Monoclonal Antibody IMC-A12 and Doxorubicin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaI/IINCT00720174
    recruiting
    Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
    INCT00655655
    recruiting
    A Combination Study With MK8669 and MK0646 in Patients With Advanced CancerINCT00730379
    recruiting
    Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by SurgeryINCT00792545
    recruiting

    Angiogenesis Inhibitors

    Trial Name (click for link)PhaseID & Status
    Safety Study of IMC-18F1 to Treat Advanced Solid Tumors in Subjects that no Longer Respond to Standard TherapyINCT00782002
    Recruiting

    Other Trials

    Trial Name (click for link)PhaseID & Status
    Sutent and Radiation as Treatment for Limited Extent Metastatic CancerI/IINCT00463060
    recruiting
    Safety Study of GL-ONC1, and Oncolytic Virus, in Patients With Advanced Solid Tumors INCT00794131
    Recruting
    Surgery in Treating Patients With Liver Metastasis From Gastrointestinal Stromal Tumor IINCT00769782
    recruiting
    A Study of Oral PX-478 in Advanced Solid Tumors or LymphomaINCT00522652
    recruiting
    Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced / Metastatic Malignant GISTIINCT00359333
    recruiting
    Doxyrubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot be Removed by SurgeryINCT00098579
    recruiting
    FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaIINCT00112463
    not recruiting
    Radiation Therapy as Palliative Treatment of GIST (GIST-RT)I-IINCT00515931
    recruiting

    Observational and Diagnostic Trials

    Trial Name (click for link)PhaseID & Status
    Studying Stem Cells in Patients With Primary or Metastatic Solid Tumors not apllic.NCT00512902
    recruiting
    Gastrointestinal Stromal Tumors (GIST) Registrynot
    applic.
    NCT00507273
    recruiting
    11C-Acetate PET/CT Non-FDG-Avid Tumorsnot
    applic.
    NCT00687778
    recruiting



  • back to top